Quanta Therapeutics Reports KRAS Colorectal Cancer Results
Clinical trial data presented in Spain highlight response rates for combinations involving the drug candidate QTX3034.
Updated on Oct. 24, 2026 in Cancer
Live Poll
Are new targeted cancer treatments reliable enough to improve long-term outcomes for most patients?
Quanta Therapeutics released clinical trial results for its KRAS G12D inhibitor QTX3034 at the 2026 European Society for Medical Oncology Congress. The study evaluated QTX3034 in combination with cetuximab and chemotherapy for patients with metastatic colorectal cancer.
Why it matters
These combinations aim to address resistance mechanisms in patients with KRAS G12D mutations, a challenging profile in metastatic colorectal cancer. The company is now pivoting toward the advancement of its pan-KRAS inhibitor QTX6255.
The QTX3034 and chemotherapy combination achieved a 50% overall response rate and a 90% disease control rate. Most patients also experienced over 90% clearance in G12D ctDNA levels during the study.
The players
Quanta Therapeutics
This biotechnology firm specializes in developing high-throughput platforms that use Second Harmonic Generation optical technology to identify allosteric modulators.
The details
Researchers tested QTX3034 at 800 mg and 1200 mg dosages alongside cetuximab and mFOLFOX6 chemotherapy to treat KRAS G12D-mutant cancer. The data presented in Madrid showed that these therapeutic combinations resulted in no new safety signals.
Timeline
August 31, 2026: Clinical data cutoff date for trial results.
October 23-27, 2026: European Society for Medical Oncology Congress 2026.
4Q26: Planned IND filing for QTX6255.
Early 2027: Anticipated Phase 1 trial start for QTX6255.
The Big Picture
The presentation at the European Society for Medical Oncology Congress marks the latest disclosure in the global effort to develop KRAS-targeted cancer therapies. This research represents a significant step in validating allosteric modulation approaches for previously treatment-resistant genetic mutations.
These clinical findings suggest potential future treatment avenues for patients with metastatic colorectal cancer and specific KRAS G12D mutations. As research progresses, patients may eventually gain access to new therapeutic combinations that address resistance mechanisms not covered by current standard-of-care options.
The takeaway
The study demonstrates that combining targeted inhibitors with standard chemotherapy can achieve high disease control rates for specific genetic mutations. Patients should consult with oncologists about how emerging trial data might relate to their specific clinical profiles.
What happens next
Quanta Therapeutics plans to file an Investigational New Drug application for its pan-KRAS inhibitor QTX6255 in the fourth quarter of 2026, with a Phase 1 clinical trial projected to begin in early 2027.
Further reading
Learn more about ongoing developments in this field on the Cancer page.
More information
For more details on the company research, visit the Quanta Therapeutics official website.
Source note: This article includes information reported by The Manila times.
Live Poll
Are new targeted cancer treatments reliable enough to improve long-term outcomes for most patients?
